Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
Assessment of the Prognostic Role of Systemic Inflammatory Index, Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
1 other identifier
observational
36
0 countries
N/A
Brief Summary
the goal of this observational study is Assesment of systemic inflammatory index (SII) , system inflammation response index (SIRI) and CRP Albumin ratio(CAR) as biomarkers for ALL prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 27, 2024
CompletedStudy Start
First participant enrolled
November 1, 2024
CompletedFirst Posted
Study publicly available on registry
November 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2025
CompletedNovember 5, 2024
November 1, 2024
1 year
October 27, 2024
November 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment of C-reactive protein to Albumin ratio(CAR) as a biomarker for acute lymphoblastic leukemia prognosis
Assessment of C-reactive protein to Albumin ratio(CAR) as a biomarker for acute lymphoblastic leukemia prognosis
one year
Secondary Outcomes (1)
Assessment of systemic inflammatory index (SII) as a biomarker for acute lymphoblastic leukemia prognosis
one year
Study Arms (2)
Diseased group
36 patients with acute lymphoblastic leukemia will be included
Control group
36 healthy people will be included
Eligibility Criteria
Newly diagnosed ALL patients that admitted to the South Egypt Cancer Institute and not received any treatment.
You may qualify if:
- Newly diagnosed ALL patients that admitted to the South Egypt Cancer Institute and not received any treatment.
You may not qualify if:
- Presence of other hematological disorders( other than ALL)
- History of other malignancies, or relapsed ALL.
- Patients under chemotherapy or radiotherapy. 3- Signs of inflammation 5- Evidence of autoimmune disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
di Masi A. Human Serum Albumin: From Molecular Aspects to Biotechnological Applications. Int J Mol Sci. 2023 Feb 17;24(4):4081. doi: 10.3390/ijms24044081.
PMID: 36835490RESULTTang HN, Pan BH, Wang L, Zhu HY, Fan L, Xu W, Li JY. C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases. Transl Oncol. 2021 Apr;14(4):101035. doi: 10.1016/j.tranon.2021.101035. Epub 2021 Feb 11.
PMID: 33582571RESULTRoberts KG, Mullighan CG. The Biology of B-Progenitor Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med. 2020 Jul 1;10(7):a034835. doi: 10.1101/cshperspect.a034835.
PMID: 31653664RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Asmaa zhran
Assiut University
- STUDY DIRECTOR
Doaa Temeric
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
October 27, 2024
First Posted
November 5, 2024
Study Start
November 1, 2024
Primary Completion
November 1, 2025
Study Completion
November 1, 2025
Last Updated
November 5, 2024
Record last verified: 2024-11